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Abstract
Background—Current treatment strategies to stratify exacerbation risk rely on history of ≥2 
events in the previous year. To understand year-to-year variability and factors associated with 
consistent exacerbations over time, we present a prospective analysis of the SPIROMICS cohort.
Methods—We analyzed SPIROMICS participants with COPD and three years of prospective 
data (n=1,105). We classified participants according to yearly exacerbation frequency. Stepwise 
logistic regression compared factors associated with individuals experiencing ≥1 AECOPD in 
every year for three years versus none.
Results—During three years follow-up, 48·7% of participants experienced at least one 
AECOPD, while the majority (51·3%) experienced none. Only 2·1% had ≥2 AECOPD in each 
year. An inconsistent pattern (both years with and years without AECOPD) was common (41·3% 
of the group), particularly among GOLD stages 3 and 4 subjects (56·1%). In logistic regression, 
consistent AECOPD (≥1 event per year for three years) as compared to no AECOPD were 
associated with higher baseline symptom burden assessed with the COPD Assessment Test, 
previous exacerbations, greater evidence of small airway abnormality by computed tomography, 
lower Interleukin-15 (IL-15) and elevated Interleukin-8 (IL-8).
Conclusions—Although AECOPD are common, the exacerbation status of most individuals 
varies markedly from year to year. Among participants who experienced any AECOPD over three 
years, very few repeatedly experienced ≥2 events/year. In addition to symptoms and history of 
exacerbations in the prior year, we identified several novel biomarkers associated with consistent 
exacerbations, including CT-defined small airway abnormality, IL-15 and IL-8.
INTRODUCTION
Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are important 
events in the course of disease. AECOPD are associated with poor quality of life1 and more 
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rapid decline in lung function.2,3 The ECLIPSE investigators suggested that individuals with 
two or more exacerbations in a given year represent a distinct “frequent exacerbator” 
phenotype.4 The current Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
Guide to Chronic Obstructive Pulmonary Disease (COPD) Diagnosis and Management uses 
a threshold of two or more AECOPD in the prior year, or at least one hospitalized AECOPD, 
to identify individuals at high risk for future events (groups C and D).5 Current strategies to 
prevent exacerbations involve targeting individuals at high risk for future exacerbations, 
based on the assumption that it is possible to identify prospectively a significant number of 
high risk individuals. To assess the value of the frequent exacerbator classification and to 
understand factors associated with consistent exacerbations over time, we present a 
longitudinal, prospective analysis of exacerbations in the Subpopulations and Intermediate 
Outcome Measures in COPD Study (SPIROMICS) cohort.
METHODS
Participants and study design
SPIROMICS is a multicenter study funded by the National Health Lung and Blood Institute 
(NHLBI) (ClinicalTrials.gov Identifier: NCT01969344)6 designed to identify COPD 
subpopulations and to validate intermediate outcome measures. Participants, 40–80 years of 
age when enrolled between 2010 and 2015, were either healthy never-smokers {≤ 1 pack-
year tobacco smoking history, pre-bronchodilator FEV1/FVC≥0·70, pre-bronchodilator FVC 
≥ lower limit of normal (LLN)7 and without known lung disease or unstable cardiovascular 
disease} or were current and former smokers of >20 pack-years with and without airflow 
obstruction, with obstruction defined as post-bronchodilator FEV1/FVC≥0·70. Subjects were 
identified through a variety of means including care at academic and non-academic medical 
centers, word of mouth and existing subject registries.6 See Supplement for full list of 
participating centers. The SPIROMICS protocol was approved by the institutional review 
boards of all participating institutions; all participants gave written informed consent.
Participants were characterized by GOLD spirometric category,8 based on spirometric values 
obtained after four inhalations each of albuterol 90 μg/inhalation and ipratropium 18 μg/
inhalation. Spirometric tracings were independently reviewed. At the initial study visit 
extensive data were collected, including demographics, multiple questionnaires to assess 
symptoms and quality of life, cigarette smoke exposure, spirometry and 6-minute walk 
distance. High Resolution Cat Scan (HRCT) was performed according to study protocol.9 
Details of this baseline assessment are provided in Couper et al.6 .
Self-report exacerbation data in the year before enrollment were collected at the baseline 
visit. Prospective exacerbation data were collected every three months through a structured 
telephone questionnaire and three annual clinic visits. AECOPD were defined as health care 
utilization events (office visit, hospital admission, or Emergency Department (ED) visit for a 
respiratory “flare-up”) that involved the use of antibiotics and/or systemic corticosteroids. 
Severe AECOPD were defined as those leading to a hospitalization or ED visit. AECOPD 
were managed by the participants’ usual care providers; the study did not provide guidance 
on management.
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We measured emphysema and airway wall thickness on HRCT imaging by VIDA software 
(Coralville, IA) using a <-950 HU threshold (emphysema) and Pi10 (airway wall 
thickening).10 Parametric Response Mapping (PRM) analysis was performed using the 
Imbio Lung Density Analysis (LDA) software application (Imbio, LLC, Minneapolis, MN) 
to distinguish regions of emphysema (PRMEMPH) from regions of non-emphysematous gas 
trapping, functional small airways disease (PRMfSAD).11
Statistical Analysis
Data analysis was performed using SAS 9·4 software (SAS Institute, Cary, NC). We 
compared participants with three years of complete AECOPD data to the remainder of 
SPIROMICS participants with <3 years follow-up using two-sample t-tests for continuous 
variables and chi-square tests for categorical variables. Two regression models were built. 
First, among subjects with three years of follow-up, stepwise logistic regression was used to 
investigate factors associated with having at least one AECOPD in each of the three years 
(consistent AECOPD) versus no AECOPD in the 3-year period. Second, a stepwise zero-
inflated negative binomial model was used to examine predictors of exacerbation count 
during follow-up using all subjects with available data. Age, sex, race, current smoking 
status, clinical center of recruitment and FEV1% predicted were included in all models as 
potential confounders; follow-uptime was included as an offset in this model. For additional 
variables, a significance level of 0·05 was used as the criterion for entry or deletion at each 
stage. We considered the following additional predictors: the score on the COPD 
Assessment Test (CAT)12, five measurements obtained from the CT scans, self-reported 
history of gastroesophageal reflux disease (GERD), history of cardiovascular disease, 
depression and anxiety score from the Hospital Anxiety and Depression Scale questionnaire, 
prior exacerbation history, blood eosinophil count, white blood cell (WBC) count and 12 
biologically plausible, circulating biomarkers (Supplemental Table e1). We defined 
annualized exacerbation rates as the total number of events per person divided by the 
number of follow-up days for that person, multiplied by 365. We evaluated for collinearity 
of candidate variables. Many of the imaging variables were correlated with themselves and 
with FEV1% predicted. Collinearity can be a concern if it makes model estimation unstable 
but we did not find that to be the case. Stepwise regression was used to select variables with 
independently contributing associations after accounting for relevant confounders.
Role of the Funding Source
The study sponsor had no role in the analysis or interpretation of the data. Nor was the study 
sponsor involved in the writing of the manuscript or decision to submit the paper for 
publication. The corresponding author had full access to the data and final responsibility for 
the decision to submit for publication.
RESULTS
Study subject characteristics
Here we focused on patterns of AECOPD in subjects with COPD and three years of 
complete AECOPD data (n= 1,105), selected from among SPIROMICS participants with 
COPD (n=1,843) (Figure 1). Their baseline characteristics, including the degree of airflow 
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obstruction, are presented in Table 1. The largest group of subjects was GOLD 2, with 
relatively equal numbers of GOLD 1 and 3 subjects, followed by GOLD 4. Due to staggered 
recruitment and protocol-determined termination of data collection, some SPIROMICS 
subjects with COPD (n=738) did not have three complete years of exacerbation data 
(Supplemental Table e2). Those with complete three-year exacerbation data were slightly 
older, less likely current smokers, had a higher FEV1 and lower CAT score than subjects for 
whom complete three-year exacerbation data were not available (Supplemental Table e2).
Among the 1,105 subjects with complete data, 48·7% experienced at least one AECOPD 
during three years of follow-up, while the majority (51·3%) remained exacerbation-free 
(Table 1 and Supplemental Table e3). Exacerbation frequency increased with worsening 
airflow obstruction (GOLD category). In GOLD categories 3 or 4, a majority of individuals 
experienced at least one exacerbation during three years of follow-up (66·0% and 83·9%, 
respectively). Overall, 49·8% of individuals who had an AECOPD had at least one severe 
exacerbation, as identified by ED visit or hospitalization. Although exacerbations were more 
often severe in individuals with greater airflow obstruction, we found that even in GOLD 
stage 1 disease, 10·9% of individuals had at least one severe event. Furthermore, among 
GOLD stage 1 subjects who experienced at least one exacerbation, 44% had at least one 
exacerbation that was severe (Supplemental Tables e3).
Patterns of exacerbations over time
Depicting the patterns of AECOPD over three years revealed marked year-to-year 
heterogeneity (Figure 2). The most frequent pattern was no exacerbations in any year 
(51·3% of subjects). The next most common status (41·3% of subjects, Supplemental Table 
e4) was “inconsistent exacerbators” who had both years in which they experienced 
exacerbations and years without exacerbations during the three years of follow-up. 
Considerably fewer had at least one exacerbation each year (n=82, 7·4%). Only a small 
minority (n=23, 2·1%) of the current analysis group had two or more exacerbations in each 
of three study years and would be consistently classified as frequent exacerbators by the 
ECLIPSE criterion.
Examination of year-by-year exacerbation status demonstrated both that absence of 
AECOPD over three years follow-up was common, and that individuals frequently changed 
status between years (Figure 3). These changes in status do not simply represent acquisition 
of AECOPD in previously exacerbation-free individuals, as status changed in both 
directions. We repeated this analysis restricted to individuals with GOLD 1–2 and 3–4 
disease and obtained similar results in each instance (Supplemental Figures e1–e2). Change 
in exacerbation pattern from year to year was a common finding in all GOLD groups.
In an analysis restricted to individuals with GOLD 2–4 disease, the pattern of inconsistent 
AECOPD was most frequent, while 43·4% of those participants did not experience any 
exacerbations during three years of follow-up (Supplemental Figure e3). A distinct minority 
fell into a consistent frequent exacerbator category throughout the three years of follow-up. 
Although exacerbations were more common in individuals with more severe airflow 
obstruction, even in GOLD categories 3 and 4, inconsistent AECOPD was the most common 
Han et al. Page 5
Lancet Respir Med. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
status, followed by no events. Only 4% of subjects in these categories were characterized as 
a frequent exacerbator during each year of follow-up (Supplemental Figure e2).
Due to staggered recruitment, some participants were recruited later and did not have an 
opportunity to provide three full years of follow-up. Given subtle baseline differences 
between the 1,105 individuals with complete three years follow-up data and the 738 for 
whom data were incomplete, we conducted a similar analysis combining retrospectively 
reported AECOPD in the year before study entry with the first two years of follow-up. Using 
this approach, complete data for three years (one retrospective and two prospective) were 
available for 1,471 subjects. Again, the pattern of exacerbation frequency was remarkably 
similar to that of the entirely prospective data (Supplemental Figure e4). Thus, in this cohort, 
most individuals demonstrated either a consistent pattern of no AECOPD or an inconsistent 
pattern of variation from year to year, with relatively few having consistent AECOPD each 
year.
Factors associated with consistent exacerbations
The various clinical characteristics of the patient groups with differing patterns of 
exacerbations during follow-up are enumerated in Table 1 and Supplemental Table e5. To 
identify clinical or biological characteristics associated with consistent AECOPD over time, 
we first compared individuals with at least one exacerbation in every year during three years 
of follow-up (consistent exacerbators) to those who experienced no exacerbations during 
follow-up using stepwise logistic regression. Variables associated with consistently 
experiencing AECOPD included higher CAT score, previous AECOPD, increased 
PRMfSAD, lower circulating IL-15 and elevated IL-8 (Table 2). FEV1% predicted was 
associated with consistent exacerbations at the p=0·05 level. Blood eosinophils did not 
predict exacerbation group in any analyses. Visual CT analysis was available in a subset of 
individuals (n=286). When tested in the model shown in Table 2, visual bronchiectasis was 
not associated with consistent exacerbations, p=0.58.
Factors associated with exacerbation rate
In a separate analysis, we utilized a step-wise, zero-inflated negative binomial regression 
model to examine predictors of exacerbation rate using all subjects with any available 
follow-up data (Supplemental Table e6, univariate associations in Table e7). As with the 
logistic model examining associations with consistent exacerbations, higher CAT score and 
prior exacerbation history were significantly associated with exacerbation rate. However, in 
this analysis, female gender, CT based air trapping and greater VCAM1 (vascular cell 
adhesion molecule 1) were also associated with higher exacerbation rate during follow-up. 
While FEV1% predicted was associated with exacerbation rate in univariate analysis (Table 
e7), it was not significant in the multivariate analysis. We also ran a subgroup analysis using 
only frequent exacerbators in the zero-inflated negative binomial model to determine the 
relationship between eosinophils and exacerbations. No significant effect for eosinophils 
was seen, p=0.16 (full model adjusted for covariates, Supplemental Table e8) and 0.10 
(eosinophils alone). In fact, we saw a nominally decreasing risk of exacerbations (incident 
rate ratio < 1) as eosinophils increased.
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Exacerbation treatment
We also performed analyses to examine treatment received for the exacerbation. Analyzing 
those with complete 3 years of follow-up, we examined the first event among those who had 
at least one AECOPD in the first year. Among the individuals in the inconsistent 
exacerbators group, 38% received antibiotics only, 8% systemic steroids only and 54% both 
antibiotics and systemic steroids. Among individuals in the consistent exacerbators group, 
29% received antibiotics only, 7% received steroids only and 64% both. To understand how 
treatment might vary from event to event, we also compared the first treated event in year 1 
to the first treated event in year 2. Significant variation in treatment is evident (Supplemental 
Table e9), but it would appear that among individuals who received both antibiotics and 
steroids for the first event (n=30), a significant number received both again for the second 
event (n=19, 63%).
DISCUSSION
In a large cohort of highly characterized participants with a broad range of spirometric 
severity, we report that the most durable AECOPD phenotype is the lack of events over a 
three-year period, seen in 51·3% of individuals. Among participants experiencing at least 
one exacerbation over three years, exacerbation status was highly variable, with only 7·4% 
of the cohort consistently experiencing at least one exacerbation each year and only 2·1% 
experiencing ≥2 exacerbations in every year. Limiting the analysis to GOLD 3 and 4 
individuals, 1·2% experienced ≥2 exacerbations in every year. In multivariate analysis, 
consistent exacerbations as defined by ≥1 AECOPD per year in every year of follow-up 
were associated with higher CAT score, prior history of exacerbations, CT defined small 
airway abnormality, lower circulating IL-15 and higher circulating IL-8.
The impact of AECOPD should not be underestimated. Those suffering frequent 
exacerbations experience poorer quality of life.13 Mortality in the year following a 
hospitalized exacerbation is estimated to be as high as 21%.14 Caring for COPD remains 
expensive, with US estimates at nearly $50 billion in 2007;15 much of this cost is related to 
AECOPD management. Although therapy can reduce exacerbation frequency,16 better 
treatments are still needed. Accordingly, the ability to identify individuals at high risk for the 
purposes of targeted treatment and research is of paramount importance.
In SPIROMICS, only 2·1% of COPD participants experienced ≥2 exacerbations in each of 
three years follow-up. Even in the more severe ECLIPSE cohort, only 12% of subjects 
consistently experienced two or more exacerbations per year during three years follow-up.17 
Data from the ECLIPSE study suggested that subjects with a history of ≥2 exacerbations in a 
previous year represent a relatively stable “frequent exacerbator” phenotype associated with 
persistently increased inflammation.4 In ECLIPSE, between Years 1 and 2, 39% of patients 
changed from a frequent exacerbator (≥2 AECOPD) to infrequent exacerbator (0–1 
AECOPD), while 17% changed from infrequent exacerbator to frequent exacerbator.17 
Limiting the SPIROMICS analysis to GOLD 2–4 participants, between Years 1 and 2, 52% 
of frequent exacerbators became infrequent exacerbators, while 14% of infrequent 
exacerbators became frequent exacerbators (Supplemental Figure e3). In a smaller study, 
Brusse-Keizer, et al. also reported on stability of exacerbation frequency in a moderate to 
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severe COPD cohort of 121 patients.18 Similar to SPIROMICS, between enrollment and 
Year 1, 42% of frequent exacerbators changed to infrequent exacerbators, while 21% of 
infrequent exacerbators changed to frequent exacerbators. Although these various 
populations were recruited by separate investigative groups during different time periods, 
necessitating caution in making direct comparisons, in sum they demonstrate the regularity 
with which individuals change exacerbation categories.
In the SPIROMICS cohort, we also demonstrate an association between consistent 
AECOPD and greater functional small airway abnormality, PRMfSAD, as detected via 
recently developed CT metrics. This abnormality has also previously been identified as a 
marker of more rapid lung function decline.3 Prior analyses of exacerbations have 
demonstrated an association between segmental level wall thickness measured at the fourth 
generation and exacerbations, but PRMfSAD was not included in that analysis.19 In the 
current study, we found that PRMfSAD was strongly associated with consistent 
exacerbations. Associations between low IL-15 and higher IL-8 and consistent exacerbations 
were also seen. In a separate analysis examining associations with exacerbation rate using a 
zero-inflated negative binomial model, prior AECOPD, CAT score and % gas trapping on 
CT (another indirect measure of small airway abnormality) were associated with 
exacerbation count, similar to the first model. However, several other significant associations 
emerged including female sex and higher levels of circulating VCAM1. IL-15 and IL-8 were 
not significant in this alternative model, nor was FEV1% predicted. Hence, it is plausible 
that the factors associated with consistent exacerbations differ from exacerbation rates in the 
broader group. Interestingly, although FEV1% predicted was important in univariate analysis 
and exacerbations were more common in subjects with more severe airflow obstruction, 
multivariate analyses yielded limited evidence to support an independent contribution of this 
parameter. In two different multivariate analyses, FEV1% predicted appeared at the 0.05 
significance level in one and was not found to be significant in the other. This is likely a 
function of close interaction between that parameter and other important patient 
characteristics, such as CT features of COPD.
Ultimately these data have implications for stratifying patients both in clinical practice and 
for research. Frequent exacerbator status defined by ≥2 exacerbations in every year is 
distinctly uncommon; in our cohort, only 2·1% in GOLD 1–4 and 1·2% among GOLD 3–4. 
This variability in yearly exacerbation rates could stem from failure to consider the multiple 
triggers that initiate exacerbations. Whether an individual subject encounters a potent trigger 
for exacerbation within any given year may determine whether or not that individual 
experiences an exacerbation in that year. Current GOLD stratification schema use a history 
of ≥2 exacerbations in the previous year as one way to identify those at increased risk for 
future events.5 The frequency of these events and their consistency across broad range of 
patient groups has not been thoroughly evaluated. Although our data support a relationship 
between previous and future exacerbations, they also indicate that exacerbation frequency is 
highly variable over time. Among individuals who inconsistently exacerbate, factors 
extrinsic to the individual such as specific exposures may play a strong role in exacerbation 
occurrence, making these events difficult to predict.
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We acknowledge limitations to this analysis. This cohort is not population-based and 
therefore may be biased, as types of patients evaluated at academic centers may differ from 
the general COPD patient population. By design, this cohort also has more mildly affected 
individuals than other cohort studies such as ECLIPSE where only GOLD 2–4 individuals 
were included. Decisions concerning treatment of COPD were by the patients’ own 
physicians and were not guided by study protocol. Such analyses also may differ based on 
the types of exacerbations studied. Here we chose to examine moderate to severe events 
requiring a health care utilization visit. Daily diary data from the Exact Pro instrument was 
captured in a subset of individuals and will be examined in future analyses. Strengths of this 
study, however, include rigorously collected data through systematic and frequent contacts 
with participating subjects; inclusion of participants exhibiting a wide range of disease 
severity; and detailed phenotyping data including CT and blood biomarkers.
CONCLUSIONS
We report that in a COPD cohort (GOLD 1–4) not selected for recent exacerbations, 
AECOPD frequency varied greatly from year to year. The two most common phenotypes 
were no exacerbations over three years (51·3% of subjects) and the “inconsistent 
exacerbator”, who changed exacerbation status from year to year (41·3% of subjects). Those 
with two or more exacerbations in every year represented only approximately 2·1% of our 
cohort. We did identify a group of individuals (7·4% of subjects) who consistently 
exacerbated over time as defined by one or more exacerbations every year during three years 
of follow-up. Among these individuals, in addition to prior exacerbation history and CAT 
score, we also identified CT defined small airway abnormality, low IL-15 and elevated IL-8 
as being predictors of consistent exacerbation status. Among individuals who inconsistently 
exacerbate, it is plausible that factors beyond the individual such as exposure to external 
triggers play a strong role in exacerbation occurrence making these events more difficult to 
predict.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Research in Context
Evidence before this study
We searched PubMed between September 1, 2010, and January 1, 2016, to identify 
studies that evaluated frequent exacerbators. We used the search term “frequent” in 
combination with “COPD” and “exacerbation.” The search was limited to human studies 
in English language. Studies reporting on nine, general population COPD cohorts were 
identified that described frequent exacerbator populations. These studies reported a range 
in prevalence of frequent exacerbators defined as individuals with ≥2 exacerbations in 
any one year between 14% and 34%. Only one other study in addition to ECLIPSE was 
identified that examined the stability of the frequent exacerbator phenotype over time, 
noting exacerbation frequency prior to the study was not a predictor for being a frequent 
exacerbator during the first year of the study.
Added value of this study
In this study, we extend the results of ECLIPSE to a GOLD 1–4 patient population. 
While approximately half of all patients experienced at least one AECOPD during three 
years of follow-up, experiencing ≥2 AECOPD in each year was relatively uncommon. 
Significant variation from year to year in meeting the “frequent exacerbator” criteria of 
≥2 events per year was seen.
Implications of all the available evidence
Experiencing ≥2 AECOPD in the prior year is currently part of the criteria for GOLD 
ABCD grading criteria and has previously been proposed as a key criterion to identify 
patients for therapeutic trials. However, the data presented here suggest that a subject’s 
AECOPD frequency is subject to significant fluctuation. Though exacerbation frequency 
is an important parameter, we demonstrate significant instability in this measure that 
potentially limits the clinical value of a threshold of ≥2 AECOPD in the prior year. As 
such, this criterion may not be best way to identify individual patients at increased risk 
for AECOPD and subsequently classify individuals for pharmacotherapeutic decision 
making.
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Figure 1. 
CONSORT diagram of SPIROMICS participants used in current analysis.
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Figure 2. 
Frequency of AECOPD in each of three years in COPD subjects (n=1,105). Data are 
presented as percentages of subjects with each category of AECOPD frequency, by GOLD 
stage and in the entire group. A, no exacerbation in each of three years; B, ≥1 exacerbation 
in each of three years; C, ≥2 exacerbation in each of three years; D, inconsistent AECOPD 
pattern in the three years.
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Figure 3. 
Stability of AECOPD frequency patterns over three years of prospective follow-up in GOLD 
1–4 subjects. The proportion of participants with given AECOPD frequencies in the first 
year of follow-up are sequentially subdivided by their exacerbation frequency in each of the 
subsequent years. Final column is the proportion, out of all participants, in the final category.
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Table 2
Results of stepwise logistic regression analysis to examine characteristics associated with having one or more 
exacerbations during each year of three years of follow-up versus zero exacerbations among GOLD 1–4 
participants, n=394.
Characteristic Odds Ratio 95% Confidence Interval P-value
Age 0·82 0·45, 1·50 0·52
Gender (female) 1·41 0·66, 3·04 0·38
Race (white v. Other) 0·70 0·25, 2·00 0·51
Current smoking 0·62 0·23, 1·63 0·33
FEV1 % predicted 0·80 0·64, 1·00 0·05
CAT Score 1·11 1·06, 1·17 <0·0001
AECOPD in the year prior to baseline 5·22 2·38, 11·48 <0·0001
PRMfSAD 1·51 1·07, 2·14 0·02
IL15 (ng/mL) 0·04 0·001, 0·82 0·04
IL8 (pg/mL) 1·02 1·00, 1·04 0·046
% predicted FEV1 was re-parameterized by increments of 10 percentage points; FEV1, forced expiratory volume one second; CAT, COPD 
assessment test; AECOPD, acute exacerbation of COPD; PRMfSAD, parametric response mapping functional small airways disease; IL15, 
interleukin 15; IL8, interleukin 8. Model also adjusted for clinical center of recruitment. Using just the “confounders” (site, age, sex, race, current 
smoking, FEV1% predicted) AUC = 0.84, 95% CI (0.80, 0.89). Using the full model, AUC = 0.92, 95% CI (0.88, 0.95)
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